{"organizations": [], "uuid": "9cae5efece0dccac87fe0c086955433dbe1bdcbb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-gw-pharma-announces-unanimous-posi/brief-gw-pharma-announces-unanimous-positive-result-of-fda-advisory-committee-meeting-idUSFWN1RW0V3", "country": "US", "domain_rank": 408, "title": "BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.724, "site_type": "news", "published": "2018-04-20T01:37:00.000+03:00", "replies_count": 0, "uuid": "9cae5efece0dccac87fe0c086955433dbe1bdcbb"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-gw-pharma-announces-unanimous-posi/brief-gw-pharma-announces-unanimous-positive-result-of-fda-advisory-committee-meeting-idUSFWN1RW0V3", "ord_in_thread": 0, "title": "BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting", "locations": [], "entities": {"persons": [{"name": "epidiolex", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "gw pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda advisory committee", "sentiment": "negative"}, {"name": "gw pharmaceuticals plc", "sentiment": "negative"}, {"name": "nda", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - GW Pharmaceuticals PLC:\n* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY\n* GW PHARMACEUTICALS PLC - EPIDIOLEX WAS GENERALLY WELL TOLERATED WITH MOST ADVERSE EVENTS REPORTED AS MILD OR MODERATE\n* GW PHARMACEUTICALS PLC - PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-20T01:37:00.000+03:00", "crawled": "2018-04-20T11:27:08.006+03:00", "highlightTitle": ""}